Choosing the right non-clinical CRO

Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical and scientific skills. In selecting a CRO, the sponsor typically [...]

By |2018-09-12T14:07:14+00:00September 19th, 2018|Toxicology, Press|Comments Off on Choosing the right non-clinical CRO

Safety Must Be Prioritized In Drugs for Cancer

Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several  years. Though there is a [...]

By |2018-07-11T10:00:27+00:00May 16th, 2018|Press|Comments Off on Safety Must Be Prioritized In Drugs for Cancer

Attitude Toward Safety in Needs to Change

A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues [...]

By |2018-06-27T16:32:28+00:00February 20th, 2018|Press|Comments Off on Attitude Toward Safety in Needs to Change

Professor Ruth Roberts Receives International Award

Professor Ruth Roberts – co-founder and director of nonclinical safety company, ApconiX based at Alderley Park, Cheshire – is the first non-US-based scientist to receive a prestigious international award for professionals specialising in drug and chemical safety. She is only the tenth person to receive the US-based Society of Toxicology (SOT) Founders Award, presented for “outstanding leadership in fostering the role of [...]

By |2018-07-11T14:02:02+00:00December 15th, 2017|Press|Comments Off on Professor Ruth Roberts Receives International Award

ApconiX Achieves Five-Fold Turnover Boost

The business has just received the accolade of Start-Up of the Year at the 17th awards hosted by BioNow, the northern England bio-medical and life sciences membership organisation. The company’s early success is based on delivering expertise in safety toxicology and ion channel electrophysiology to a changing pharmaceutical sector, in which more companies are outsourcing [...]

By |2018-07-11T14:31:30+00:00December 7th, 2017|Press|Comments Off on ApconiX Achieves Five-Fold Turnover Boost

Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]

By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure

Sygnature Discovery Forms a Strategic Alliance with ApconiX

02 October 2017 – Nottingham and Alderley Park, UK – Sygnature Discovery, the UK's largest independent provider of integrated drug discovery resource and expertise, has announced it is to work in partnership with ApconiX, experts in non-clinical safety strategies and ion channel screening, to offer a broader range of drug discovery services. Dr Paul Clewlow, [...]

By |2018-06-06T14:50:03+00:00October 3rd, 2017|Press|Comments Off on Sygnature Discovery Forms a Strategic Alliance with ApconiX

ApconiX Announce Their Alliance with PhysioStim.

The European Centre of Excellence for preclinical cardiovascular electrophysiology. The ApconiX team is pleased to announce their alliance with PhysioStim to create a new Centre of Excellence dedicated to cardiac safety studies. Both companies team up to offer a complete range of services in nonclinical cardiovascular electrophysiology. ApconiX, based at Alderley Park in the U.K. [...]

By |2018-06-20T16:06:07+00:00September 21st, 2017|Ion Channels, Press|Comments Off on ApconiX Announce Their Alliance with PhysioStim.

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure